Keros Therapeutics Inc (KROS)

01:00 AM

Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.

01:00 AM

May 22, 2026

KROS Turns to Next Wave of TGF-Beta Muscle Therapies - The Globe and Mail

May 22, 2026

May 22, 2026

Should You Buy KROS After Q1 Miss and Takeda Deal Reset? - The Globe and Mail

May 22, 2026

May 22, 2026

KROS Stock Guide to Rinvatercept in DMD and ALS for 2026 - The Globe and Mail

May 22, 2026

May 21, 2026

Keros Therapeutics (KROS) Q1 2026 Disappoints — EPS $-1.21 Below $-1.04 ViewsQuarterly Earnings Report - Newser

May 21, 2026

May 21, 2026

Keros Therapeutics, Inc. (KROS) reports Q1 loss, misses revenue estimates - MSN

May 21, 2026

May 21, 2026

Lexington, MA Biopharma Co. Reports Q1 2026 Financials, Makes R&D Plans - Streetwise Reports

May 21, 2026

May 20, 2026

Lexington, MA Biotech Pushes DMD Phase 2 Start to 3Q26 on Regulatory Hurdles - Streetwise Reports

May 20, 2026

May 20, 2026

Wedbush Maintains Keros Therapeutics(KROS.US) With Hold Rating, Maintains Target Price $16 - Moomoo

May 20, 2026

May 19, 2026

Director at Keros Therapeutics (KROS) buys 1,000 shares under 10b5-1 plan - Stock Titan

May 19, 2026

May 18, 2026

Why is Keros Therapeutics (KROS) up 2.5% since last earnings report? - MSN

May 18, 2026

May 18, 2026

Keros Therapeutics, Inc.common stock (NQ: KROS - The Chronicle-Journal

May 18, 2026

May 17, 2026

Earnings Release: Here's Why Analysts Cut Their Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target To US$21.20 - Yahoo Finance

May 17, 2026

May 17, 2026

How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24% - MSN

May 17, 2026

May 16, 2026

Truist Financial Maintains Keros Therapeutics(KROS.US) With Buy Rating - Moomoo

May 16, 2026

May 15, 2026

A Quick Look at Today's Ratings for Keros Therapeutics(KROS.US), With a Forecast Between $20 to $20 - Moomoo

May 15, 2026

May 15, 2026

Nantahala's 1.36M-share stake in Keros Therapeutics (NASDAQ: KROS) - Stock Titan

May 15, 2026

May 15, 2026

Keros Q1 Loss Wider Than Expected, Revenues Plunge Year Over Year - The Globe and Mail

May 15, 2026

May 14, 2026

Keros Therapeutics Reports Q1 2026 Financial Results: Net Loss, Cash Position, and R&D Updates - Minichart

May 14, 2026

May 14, 2026

Keros Therapeutics Releases Q1 2026 Financial Results - AlphaStreet

May 14, 2026

May 14, 2026

KROS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

May 14, 2026

May 14, 2026

Cellectar Biosciences Q1 2026: Loss Narrows 29.6% to -$1.33/Share - AlphaStreet

May 14, 2026

May 14, 2026

Keros Therapeutics, Inc. (KROS) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance

May 14, 2026

May 14, 2026

Keros Therapeutics (KROS) swings to Q1 2026 loss as Takeda revenue steps down - Stock Titan

May 14, 2026

May 14, 2026

Keros Therapeutics 1Q 2026: Revenue $367K, EPS ($1.21) — 10-Q Summary - TradingView

May 14, 2026

May 14, 2026

Takeda to advance Keros anemia drug to Phase 3 as Q1 swings to $23.7M loss - Stock Titan

May 14, 2026

May 14, 2026

Keros Therapeutics Reports Recent First Quarter 2026 Financial Results - marketscreener.com

May 14, 2026

May 14, 2026

Keros (NASDAQ: KROS) swings to Q1 2026 loss as Takeda license boost fades - Stock Titan

May 14, 2026

May 14, 2026

KROS stock: Does the Takeda deal lower dilution risk in 2026? - MSN

May 14, 2026

May 12, 2026

TradingKey - TradingKey

May 12, 2026

May 08, 2026

Top iBio (IBIO) Competitors 2026 - MarketBeat

May 08, 2026

May 08, 2026

KROS (Keros Therapeutics) Q4 earnings miss: EPS $-0.86 vs estimate $-0.64, stock slides 1.19%.Decline Risk - newser.com

May 08, 2026

May 06, 2026

What Keros Therapeutics (KROS) does that makes it resilient (Flat) 2026-05-06Top Analyst Picks - newser.com

May 06, 2026

May 05, 2026

(KROS) and the Role of Price-Sensitive Allocations - Stock Traders Daily

May 05, 2026

May 02, 2026

Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of "Hold" by Analysts - MarketBeat

May 02, 2026

Apr 29, 2026

Sarcopenia Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | TNF Pharma, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross, Mirsc - Barchart.com

Apr 29, 2026

Apr 28, 2026

Insmed (INSM) soars 5.5%: Is further upside left in the stock? - MSN

Apr 28, 2026

Apr 28, 2026

Keros Therapeutics (KROS) to Release Quarterly Earnings on Tuesday - MarketBeat

Apr 28, 2026

Apr 25, 2026

Keros gains Orphan Drug designation for Duchenne muscular dystrophy asset - MSN

Apr 25, 2026

Apr 24, 2026

Responsive Playbooks and the KROS Inflection - Stock Traders Daily

Apr 24, 2026

Apr 24, 2026

KROS|Keros Therapeutics Inc|Price:11.510|Chg%:-0.05 - TradingKey

Apr 24, 2026

Apr 23, 2026

ADAR1 Capital Management urges Keros Therapeutics for board change - MSN

Apr 23, 2026

Apr 23, 2026

Keros Therapeutics (KROS) Business Update | Q4 2025: Earnings UnderperformShared Buy Zones - Cổng thông tin điện tử tỉnh Lào Cai

Apr 23, 2026